Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...
BGB-16673 showed high overall response rates in relapsed/refractory CLL/SLL, with a notable 94.4% response at the 200-mg dose level. Safety analysis revealed that 95.6% of patients experienced ...
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...
Pirtobrutinib showed noninferiority in ORR compared to ibrutinib in BTK inhibitor-naive CLL/SLL patients, with a favorable PFS trend. Safety profiles indicated fewer adverse events with pirtobrutinib, ...
Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...
Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients ...
There have been major treatment advancements for CLL in the last decade, with future generations of drugs on the horizon. When it comes to the treatment of chronic lymphocytic leukemia, or CLL, there ...
The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy. People with CLL have a higher risk of developing skin cancers, including SCC, explained ...
A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...
For most of us, a cancer diagnosis would be the worst possible news. But a remarkable new documentary, Second Winds, captures the powerful personal journeys of three people living with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results